Preferred Label : Docetaxel;
NCIt synonyms : N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; [2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b
alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic
Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
Ester;
NCIt related terms : Taxotere;
NCIt definition : A semi-synthetic, second-generation taxane derived from a compound found in the European
yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties;
it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which
results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits
pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays
immunomodulatory and pro-inflammatory properties by inducing various mediators of
the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing
agent. (NCI04);
Alternative definition : NCI-GLOSS: A drug used together with other drugs to treat certain types of breast
cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer.
It is also being studied in the treatment of other types of cancer. Docetaxel is a
type of mitotic inhibitor.;
UNII : 15H5577CQD;
InChIKey : XCDIRYDKECHIPE-QHEQPUDQSA-N;
CAS number : 148408-66-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 148408-66-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Taxotere; Taxotere Injection Concentrate; Docecad;
Molecule name : RP56976; RP 56976;
Chemical formula : C43H53NO14.3H2O;
NSC code : 628503;
ChEBI ID : CHEBI:59809;
Codes from synonyms : NSC0628503; CDR0000508678; CDR0000045382; 32090; 164;
Origin ID : C1526;
UMLS CUI : C0246415;
See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- docetaxel [International Nonproprietary Name]
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- chemical_or_drug_is_metabolized_by_enzyme
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
https://pgtmsite.files.wordpress.com/2024/01/docetaxel_sein-_-evaluation-complete_19-decembre-07_final.pdf
2007
Canada
drug information
neoplasm, malignant
Adjuvant Therapy Clinical Trial Setting
adjuvant, nos
Childhood Breast Carcinoma
breast neoplasms
Additive
docetaxel
breast cancer
docetaxel
Adjuvant
Male Breast Carcinoma
Docetaxel
Docetaxel
Adjudicator
---
https://pgtmsite.files.wordpress.com/2024/01/docetaxel_seinneoadjuvant_pgtm_20060629.pdf
2006
Canada
drug information
neoplasm, malignant
adjuvant, nos
Docetaxel
docetaxel
Adjuvant Therapy Clinical Trial Setting
Adjuvant
breast cancer
Docetaxel
breast neoplasms
Childhood Breast Carcinoma
Male Breast Carcinoma
NEO Gene
Additive
Adjudicator
docetaxel
---
https://pgtmsite.files.wordpress.com/2024/01/docetaxel_prostate_pgtm_20050407.pdf
2005
Canada
drug information
Docetaxel
prostatism, nos
Prostate Cancer Pathway
NCI CTEP SDC Prostate Cancer Sub-Category Terminology
Prostate Carcinoma
prostate cancer
docetaxel
docetaxel
neoplasm, malignant
Prostate Cancer pT2c TNM Finding v6 and v7
prostatic neoplasms
prostate, nos
Docetaxel
malignant neoplasm prostate
Refractory Carcinoma
---
